4//SEC Filing
Hecht Beth 4
Accession 0001867096-25-000025
CIK 0001867096other
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 7:39 PM ET
Size
10.4 KB
Accession
0001867096-25-000025
Insider Transaction Report
Form 4
Hecht Beth
See Remarks
Transactions
- Award
Stock Appreciation Right
2025-01-31+300,000→ 300,000 totalExercise: $3.56Exp: 2027-03-02→ Common Stock (300,000 underlying) - Tax Payment
Common Stock
2025-01-31$3.56/sh−45,909$163,436→ 1,306,885 total - Award
Common Stock
2025-01-31+185,000→ 1,393,510 total - Tax Payment
Common Stock
2025-01-31$3.56/sh−98,375$350,215→ 1,208,510 total
Footnotes (4)
- [F1]Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2025.
- [F2]These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years.
- [F3]This stock appreciation right granted under the Company's 2018 Stock Option and Incentive Plan will vest in full on the second anniversary of the January 31, 2025 grant date, subject to continued service with the company through the vesting date.
- [F4]Upon exercise, the stock appreciation right will be settled in cash.
Documents
Issuer
Xeris Biopharma Holdings, Inc.
CIK 0001867096
Entity typeother
Related Parties
1- filerCIK 0001652410
Filing Metadata
- Form type
- 4
- Filed
- Feb 2, 7:00 PM ET
- Accepted
- Feb 3, 7:39 PM ET
- Size
- 10.4 KB